{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:12Z","timestamp":1791648432524,"version":"4.3.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is paucity of data on the risk of infection-related hospitalization among inflammatory bowel disease (IBD) patients exposed to newer biologics. Our aim was to assess the overall and comparative risk of infection-related hospitalization, among IBD patients exposed to different IBD medication classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of adult IBD patients in the Veterans Health Administration. New initiators of different IBD medication classes were identified, and the primary outcome was infection requiring hospitalization. Survival analysis methods were used to evaluate the association between time-updated IBD medications and these outcomes, adjusted for key confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 14\u2009554 IBD patients. There were 3131 infection hospitalizations over a median follow-up of 49.5\u2009months (interquartile range, 21.2-60.0 months). No other class of medication was associated with a statistically significant difference in the risk of acquiring an infection-related hospitalization compared with patients exposed to a combination therapy of anti-tumor necrosis factor (TNF) inhibitors and thiopurines (TPs). There was a significantly increased risk of gastrointestinal infections with vedolizumab (hazard ration, 1.42; 95% confidence interval, 1.13-1.80; P\u2009=\u2009.003) relative to anti-TNF inhibitors + TPs. Anti-TNF inhibitor monotherapy had a lower risk when compared with vedolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide IBD cohort, there was not an increased risk of infection-related hospitalization among patients exposed to vedolizumab, ustekinumab, and tofacitinib as compared with patients on anti-TNF inhibitor and TP combination therapy and rates of infection-related hospitalization were low overall. These findings should guide clinical decision making and patient-physician discussions when selecting a therapeutic agent with the primary emphasis on efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf218","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:53:27Z","timestamp":1756986807000},"page":"199-206","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5368-7518","authenticated-orcid":false,"given":"Nabeel","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center , Philadelphia, PA,","place":["United States"]},{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9169-6036","authenticated-orcid":false,"given":"Ramaswamy","family":"Sundararajan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvan","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Mercy Fitzgerald Hospital , Darby, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6133-8660","authenticated-orcid":false,"given":"Manthankumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-521X","authenticated-orcid":false,"given":"Janak","family":"Bahirwani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kadlec Regional Medical Center , Richland, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-3954","authenticated-orcid":false,"given":"Nadim","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center , Philadelphia, PA,","place":["United States"]},{"name":"Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2026013010460485400_izaf218-B1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026013010460485400_izaf218-B2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B3","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B11","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"2026013010460485400_izaf218-B12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B15","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared with tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B16","author":"Affairs"},{"key":"2026013010460485400_izaf218-B17","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","article-title":"Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study","volume":"16","author":"Khan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B18","first-page":"553","article-title":"Pharmaceutical approval update","volume":"39","author":"Goldenberg","year":"2014","journal-title":"P T"},{"key":"2026013010460485400_izaf218-B19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.17393","article-title":"Risk of severe and opportunistic infections and the impact of SARS-COV-2 on this risk in a nationwide cohort of patients with inflammatory bowel disease","volume":"57","author":"Khan","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026013010460485400_izaf218-B20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.cgh.2022.12.017","article-title":"Incidence of long COVID and impact of medications on the risk of developing long COVID in a nationwide cohort of IBD patients","volume":"21","author":"Khan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B21","first-page":"462","article-title":"Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis","volume":"26","author":"Khan","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010460485400_izaf218-B22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2015.08.054","article-title":"Differential effects of anti-TNF-\u03b1 and anti-IL-12\/23 agents on human leukocyte-endothelial cell interactions","volume":"765","author":"R\u00edos-Navarro","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2026013010460485400_izaf218-B24","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3748\/wjg.v24.i36.4093","article-title":"Interleukin 12\/interleukin 23 pathway: biological basis and therapeutic effect in patients with Crohn\u2019s disease","volume":"24","author":"Aggeletopoulou","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026013010460485400_izaf218-B25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2026013010460485400_izaf218-B26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2026013010460485400_izaf218-B27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B28","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor \u03b1 Antagonists vs Vedolizumab in patients with inflammatory bowel diseases","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B29","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","article-title":"Comparative risk of serious infection with Vedolizumab vs Anti-tumor necrosis factor in inflammatory bowel disease: results from nationwide Swedish registers","volume":"119","author":"Karlqvist","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026013010460485400_izaf218-B30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B31","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026013010460485400_izaf218-B32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2026013010460485400_izaf218-B33","doi-asserted-by":"crossref","first-page":"e00380","DOI":"10.14309\/ctg.0000000000000380","article-title":"Obesity is not associated with an increased risk of serious infections in biologic-treated patients with inflammatory bowel diseases","volume":"12","author":"Singh","year":"2021","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/199\/64719885\/izaf218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/199\/64719885\/izaf218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:46:16Z","timestamp":1769787976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/2\/199\/8287880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf218","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,16]]}}}